COVID Vaccine Makers Tackle Eris Variant with Updated Shots
TL;DR Summary
Shares of Moderna and Pfizer experienced fluctuations after the companies announced that their updated Covid booster shots showed promise against the EG.5 and FL 1.5.1 variants. Moderna's booster generated antibodies capable of combating the FL 1.5.1 variant, which is surging in some areas. Pfizer, BioNTech, and Moderna plan to launch vaccines in September targeting the XBB.1.5 subvariant of omicron. Despite rising hospitalization rates, demand for vaccines remains crucial as sales have declined. Currently, only 17% of the U.S. population has received an updated booster shot.
- Pfizer Stock: Covid Rally Reverses As Vaccine Makers Take On A New Variant Investor's Business Daily
- Fall COVID shots will boost protection against latest subvariants, Moderna says Ars Technica
- New Covid vaccines from Pfizer, Moderna and Novavax will likely protect against Eris variant CNBC
- Moderna stock price slump, new COVID vax, will there be demand? The Boston Globe
- Moderna's (NASDAQ:MRNA) Updated COVID Vaccine Effective Against Eris Variant - TipRanks.com TipRanks
Reading Insights
Total Reads
0
Unique Readers
9
Time Saved
2 min
vs 3 min read
Condensed
83%
488 → 85 words
Want the full story? Read the original article
Read on Investor's Business Daily